MedTrace Logo

Urin-based Point-of-Care Testing for Direct Oral Anticoagulants in Stroke Patients

NCT06037200 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-09-14

No results posted yet for this study

Summary

The goal of this study is to test a urine-based point-of-care testing device for direct oral anticoagulants in patients with stroke. The main questions are:

* Can the test identify patients with direct oral anticoagulant intake?
* Is there a time benefit of urine-based point-of-care testing compared to standard blood-based coagulation assessment?
* Is the device feasible in the setting of acute stroke care?

Conditions

Interventions

DEVICE

Urin-based test by the DOASENSE Dipstick Device

Routinely assessed urine is tested by the DOASENSE Dipstick device for presence of direct oral anticoagulants. Readout is performed after 10 minutes visually and by a automated reader.

Sponsors & Collaborators

  • University of Giessen

    lead OTHER

Principal Investigators

  • Stefan Gerner, MD · Department of Neurology, University Hospital Giessen/Germany

  • Thorsten Doeppner, MD · Department of Neurology, University Hospital Giessen/Germany

  • Hagen Huttner, MD, PhD · Department of Neurology, University Hospital Giessen/Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06037200 on ClinicalTrials.gov